Illegal melanotan II products: purity analysis and contamination screening
Cohen PA, Travis JC, Venhuis BJ.
JAMA Internal Medicine, 2014
Key finding
Only 35% of products met purity standards; 65% contained bacterial endotoxins or undeclared active ingredients; significant batch-to-batch variability.
Summary
Analysis of 17 seized and commercial melanotan II preparations, documenting purity, contamination, and consistency issues in illicit products.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on Melanotan II
Spontaneous erections and libido enhancement in men using melanotan II
International Journal of Impotence Research · 2011 · Human Pilot
Nevi development and monitoring during melanotan II therapy
Melanoma Research · 2010 · Review
Melanotan II in scleroderma and vitiligo: pilot studies of MC1R activation
Pigment Cell & Melanoma Research · 2009 · Human Pilot
Melanotan II and photoprotection: mechanisms of UV tolerance and melanosome function
Journal of Investigative Dermatology · 2008 · Animal Study
Melanocortin-based therapeutics for erection and libido dysfunction
International Journal of Impotence Research · 2006 · Review